6-carboxymethyl genistein

A novel selective oestrogen receptor modulator (SERM) with unique, differential effects on the vasculature, bone and uterus

D. Somjen, Y. Amir-Zaltsman, B. Gayer, T. Kulik, E. Knoll, N. Stern, Leejane Lu, L. Toldo, F. Kohen

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

The novel genistein (G) derivative, 6-carboxymethyl genistein (CG) was evaluated for its biological properties in comparison with G. Both compounds showed oestrogenic activity in vitro and in vivo. On the other hand G and CG differed in the following parameters: (i) only CG displayed mixed agonist-antagonist activity for oestrogen receptor (ER) α in transactivation assays and (ii) only CG was capable of attenuating oestrogen (E2)-induced proliferation in vascular smooth muscle cells and of inhibiting oestrogen-induced creatine kinase (CK) specific activity in rat tissues. On the other hand only G enhanced the stimulatory effect on CK specific activity in the uterus. In comparison to the selective oestrogen receptor modulator (SERM) raloxifene (RAL), CG showed the same selectivity profile as RAL in blocking the CK response to E2 in tissues derived from both immature and ovariectomized female rats. Molecular modelling of CG bound to the ligand binding domain (LBD) of ERβ predicts that the 6-carboxymethyl group of CG almost fits the binding cavity. On the other hand, molecular modelling of CG bound to the LBD of ERα suggests that the carboxyl group of CG may perturb the end of Helix 11, eliciting a severe backbone change for Leu 525, and consequently induces a conformational change which could position Helix 12 in an antagonist conformation. This model supports the experimental findings that CG can act as a mixed agonist-antagonist when E2 is bound to its receptors. Collectively, our findings suggest that CG can be considered a novel SERM with unique effects on the vasculature, bone and uterus.

Original languageEnglish (US)
Pages (from-to)415-427
Number of pages13
JournalJournal of Endocrinology
Volume173
Issue number3
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Selective Estrogen Receptor Modulators
Uterus
Bone and Bones
Creatine Kinase
Estrogens
6-carboxymethyl genistein
Ligands
Genistein
Vascular Smooth Muscle
Transcriptional Activation
Smooth Muscle Myocytes
Theoretical Models

ASJC Scopus subject areas

  • Endocrinology

Cite this

6-carboxymethyl genistein : A novel selective oestrogen receptor modulator (SERM) with unique, differential effects on the vasculature, bone and uterus. / Somjen, D.; Amir-Zaltsman, Y.; Gayer, B.; Kulik, T.; Knoll, E.; Stern, N.; Lu, Leejane; Toldo, L.; Kohen, F.

In: Journal of Endocrinology, Vol. 173, No. 3, 2002, p. 415-427.

Research output: Contribution to journalArticle

Somjen, D. ; Amir-Zaltsman, Y. ; Gayer, B. ; Kulik, T. ; Knoll, E. ; Stern, N. ; Lu, Leejane ; Toldo, L. ; Kohen, F. / 6-carboxymethyl genistein : A novel selective oestrogen receptor modulator (SERM) with unique, differential effects on the vasculature, bone and uterus. In: Journal of Endocrinology. 2002 ; Vol. 173, No. 3. pp. 415-427.
@article{bd0eed5005c64d55b28575e0d95385cb,
title = "6-carboxymethyl genistein: A novel selective oestrogen receptor modulator (SERM) with unique, differential effects on the vasculature, bone and uterus",
abstract = "The novel genistein (G) derivative, 6-carboxymethyl genistein (CG) was evaluated for its biological properties in comparison with G. Both compounds showed oestrogenic activity in vitro and in vivo. On the other hand G and CG differed in the following parameters: (i) only CG displayed mixed agonist-antagonist activity for oestrogen receptor (ER) α in transactivation assays and (ii) only CG was capable of attenuating oestrogen (E2)-induced proliferation in vascular smooth muscle cells and of inhibiting oestrogen-induced creatine kinase (CK) specific activity in rat tissues. On the other hand only G enhanced the stimulatory effect on CK specific activity in the uterus. In comparison to the selective oestrogen receptor modulator (SERM) raloxifene (RAL), CG showed the same selectivity profile as RAL in blocking the CK response to E2 in tissues derived from both immature and ovariectomized female rats. Molecular modelling of CG bound to the ligand binding domain (LBD) of ERβ predicts that the 6-carboxymethyl group of CG almost fits the binding cavity. On the other hand, molecular modelling of CG bound to the LBD of ERα suggests that the carboxyl group of CG may perturb the end of Helix 11, eliciting a severe backbone change for Leu 525, and consequently induces a conformational change which could position Helix 12 in an antagonist conformation. This model supports the experimental findings that CG can act as a mixed agonist-antagonist when E2 is bound to its receptors. Collectively, our findings suggest that CG can be considered a novel SERM with unique effects on the vasculature, bone and uterus.",
author = "D. Somjen and Y. Amir-Zaltsman and B. Gayer and T. Kulik and E. Knoll and N. Stern and Leejane Lu and L. Toldo and F. Kohen",
year = "2002",
doi = "10.1677/joe.0.1730415",
language = "English (US)",
volume = "173",
pages = "415--427",
journal = "Journal of Endocrinology",
issn = "0022-0795",
publisher = "Society for Endocrinology",
number = "3",

}

TY - JOUR

T1 - 6-carboxymethyl genistein

T2 - A novel selective oestrogen receptor modulator (SERM) with unique, differential effects on the vasculature, bone and uterus

AU - Somjen, D.

AU - Amir-Zaltsman, Y.

AU - Gayer, B.

AU - Kulik, T.

AU - Knoll, E.

AU - Stern, N.

AU - Lu, Leejane

AU - Toldo, L.

AU - Kohen, F.

PY - 2002

Y1 - 2002

N2 - The novel genistein (G) derivative, 6-carboxymethyl genistein (CG) was evaluated for its biological properties in comparison with G. Both compounds showed oestrogenic activity in vitro and in vivo. On the other hand G and CG differed in the following parameters: (i) only CG displayed mixed agonist-antagonist activity for oestrogen receptor (ER) α in transactivation assays and (ii) only CG was capable of attenuating oestrogen (E2)-induced proliferation in vascular smooth muscle cells and of inhibiting oestrogen-induced creatine kinase (CK) specific activity in rat tissues. On the other hand only G enhanced the stimulatory effect on CK specific activity in the uterus. In comparison to the selective oestrogen receptor modulator (SERM) raloxifene (RAL), CG showed the same selectivity profile as RAL in blocking the CK response to E2 in tissues derived from both immature and ovariectomized female rats. Molecular modelling of CG bound to the ligand binding domain (LBD) of ERβ predicts that the 6-carboxymethyl group of CG almost fits the binding cavity. On the other hand, molecular modelling of CG bound to the LBD of ERα suggests that the carboxyl group of CG may perturb the end of Helix 11, eliciting a severe backbone change for Leu 525, and consequently induces a conformational change which could position Helix 12 in an antagonist conformation. This model supports the experimental findings that CG can act as a mixed agonist-antagonist when E2 is bound to its receptors. Collectively, our findings suggest that CG can be considered a novel SERM with unique effects on the vasculature, bone and uterus.

AB - The novel genistein (G) derivative, 6-carboxymethyl genistein (CG) was evaluated for its biological properties in comparison with G. Both compounds showed oestrogenic activity in vitro and in vivo. On the other hand G and CG differed in the following parameters: (i) only CG displayed mixed agonist-antagonist activity for oestrogen receptor (ER) α in transactivation assays and (ii) only CG was capable of attenuating oestrogen (E2)-induced proliferation in vascular smooth muscle cells and of inhibiting oestrogen-induced creatine kinase (CK) specific activity in rat tissues. On the other hand only G enhanced the stimulatory effect on CK specific activity in the uterus. In comparison to the selective oestrogen receptor modulator (SERM) raloxifene (RAL), CG showed the same selectivity profile as RAL in blocking the CK response to E2 in tissues derived from both immature and ovariectomized female rats. Molecular modelling of CG bound to the ligand binding domain (LBD) of ERβ predicts that the 6-carboxymethyl group of CG almost fits the binding cavity. On the other hand, molecular modelling of CG bound to the LBD of ERα suggests that the carboxyl group of CG may perturb the end of Helix 11, eliciting a severe backbone change for Leu 525, and consequently induces a conformational change which could position Helix 12 in an antagonist conformation. This model supports the experimental findings that CG can act as a mixed agonist-antagonist when E2 is bound to its receptors. Collectively, our findings suggest that CG can be considered a novel SERM with unique effects on the vasculature, bone and uterus.

UR - http://www.scopus.com/inward/record.url?scp=0036304723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036304723&partnerID=8YFLogxK

U2 - 10.1677/joe.0.1730415

DO - 10.1677/joe.0.1730415

M3 - Article

VL - 173

SP - 415

EP - 427

JO - Journal of Endocrinology

JF - Journal of Endocrinology

SN - 0022-0795

IS - 3

ER -